Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...
The goal of CLL management is to maintain the best quality of life and treat only when patients become symptomatic from their disease. 7,8 Unlike other hematologic malignancies, CLL is a long-term, ...
In a recently published study, researchers at Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts ...
Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...
Efficacy of first-line treatment for chronic lymphocytic leukemia: A Bayesian network meta-analysis.
Incidence, predictors and outcomes of cardiovascular events in patients with chronic lymphocytic leukemia. Summary of NMA results: PFS of zanubrutinib compared with frontline treatments for TN CLL.
The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...
Fay said "the hardest chapter" of his life inspired him to create a nonprofit that initiates and inspires kind acts.
The narrative highlights the importance of creating intentional spaces of silence and mindfulness amidst the chaos of chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback